These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35491246)

  • 21. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S
    PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study.
    Wada-Isoe K; Kitayama M; Nakaso K; Nakashima K
    J Neurol Sci; 2007 Sep; 260(1-2):33-7. PubMed ID: 17459416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma Phosphorylated Tau181 and Amyloid-β42 in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People.
    Yu Y; Xia X; Meng X; Li D; Qin Q
    J Alzheimers Dis; 2023; 95(1):161-169. PubMed ID: 37482995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.
    Chaudhry A; Houlden H; Rizig M
    J Neurol Sci; 2020 Aug; 415():116886. PubMed ID: 32428759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.
    Bibl M; Mollenhauer B; Esselmann H; Lewczuk P; Klafki HW; Sparbier K; Smirnov A; Cepek L; Trenkwalder C; Rüther E; Kornhuber J; Otto M; Wiltfang J
    Brain; 2006 May; 129(Pt 5):1177-87. PubMed ID: 16600985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of cerebrospinal fluid alpha-synuclein in dementia with Lewy body.
    Bousiges O; Blanc F
    Geriatr Psychol Neuropsychiatr Vieil; 2018 Sep; 16(3):305-310. PubMed ID: 30168437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
    J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies.
    van der Zande JJ; Gouw AA; van Steenoven I; van de Beek M; Scheltens P; Stam CJ; Lemstra AW
    Neurology; 2020 Aug; 95(6):e662-e670. PubMed ID: 32636325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease.
    Shimizu S; Hirao K; Kanetaka H; Namioka N; Hatanaka H; Hirose D; Fukasawa R; Umahara T; Sakurai H; Hanyu H
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):184-192. PubMed ID: 26233438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer's disease.
    Blanc F; Colloby SJ; Cretin B; de Sousa PL; Demuynck C; O'Brien JT; Martin-Hunyadi C; McKeith I; Philippi N; Taylor JP
    Alzheimers Res Ther; 2016 Jul; 8():31. PubMed ID: 27484179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease.
    Kurihara M; Komatsu H; Sengoku R; Shibukawa M; Morimoto S; Matsubara T; Arakawa A; Orita M; Ishibashi K; Mitsutake A; Shibata S; Ishiura H; Adachi K; Ohse K; Hatano K; Ihara R; Higashihara M; Nishina Y; Tokumaru AM; Ishii K; Saito Y; Murayama S; Kanemaru K; Iwata A
    Neurology; 2023 Mar; 100(10):e1009-e1019. PubMed ID: 36517236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of semiquantitative assessment of regional binding potential in 123I-FP-CIT SPECT for the differentiation of frontotemporal dementia, dementia with Lewy bodies, and Alzheimer's dementia.
    Spehl TS; Frings L; Hellwig S; Weiller C; Hüll M; Meyer PT; Amtage F
    Clin Nucl Med; 2015 Jan; 40(1):e27-33. PubMed ID: 25140560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain perfusion in dementia with Lewy bodies and Alzheimer's disease: an arterial spin labeling MRI study on prodromal and mild dementia stages.
    Roquet D; Sourty M; Botzung A; Armspach JP; Blanc F
    Alzheimers Res Ther; 2016 Jul; 8():29. PubMed ID: 27401267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.